CirCe01 Study: Evaluation of the Use of Circulating Tumour Cells to Guide Chemotherapy From the 3rd Line of Chemotherapy for Metastatic Breast Cancer
Phase III multicentre, randomized, open-label study comparing early evaluation of the
efficacy of chemotherapy by determination of circulating tumour cells versus conventional
clinical and radiological evaluation.
Interventional
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic
Overall Survival
Overall survival (from date of randomization
4 years
No
PIERGA Jean-Yves, MD
Principal Investigator
Institut Curie
France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
IC 2009-03
NCT01349842
January 2010
Name | Location |
---|